Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871

CLINICAL CANCER RESEARCH

Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,796

erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

Fiore, P. P. D., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,011

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., & Gibson, K. H. (2002) · PubMed · doi:10.7270/q2pc374f · Cited by 925

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 834

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Ranson, M., Hammond, L. A., Ferry, D. K., Kris, M. G., Tullo, A. B., Murray, P. I., Miller, V. A., Averbuch, S. D., Ochs, J., Morris, C. Q., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 764

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761

Drug binding to human alpha-1-acid glycoprotein in health and disease.

Kremer, J. M., Wilting, J., & Janssen, L. H. M. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00015-8 · Cited by 584

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Herbst, R. S., Maddox, A., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J. M., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718

Clinical pharmacokinetics of tyrosine kinase inhibitors

van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503

Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes

Li, J., Zhao, M., He, P., Hidalgo, M. M., & Baker, S. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0088 · Cited by 310

Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules

Kourounakis, A. P., Xanthopoulos, D., & Tzara, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21634 · Cited by 314

Toward precision medicine in glioblastoma: the promise and the challenges

Prados, M. D., Byron, S. A., Tran, N. L., Phillips, J. J., Molinaro, A. M., Ligon, K. L., Wen, P. Y., Kuhn, J. G., Mellinghoff, I. K., de Groot, J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov031 · Cited by 231

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Ling, J., Johnson, K. A., Miao, Z., Rakhit, A. K., Pantze, M. P., Hamilton, M., Lum, B. L., & Prakash, C. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007765 · Cited by 224

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

Li, J., Cusatis, G., Brahmer, J. R., Sparreboom, A., Robey, R. W., Bates, S. E., Hidalgo, M. M., & Baker, S. D. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.3.3763 · Cited by 191

The Biochemistry of Drug Metabolism – An Introduction

Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790032 · Cited by 180

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155

Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain

Wu, C., Li, Y. L., Wang, Z. M., Li, Z., Zhang, T. X., & Wei, Z. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.011 · Cited by 149

Single-Dose Clinical Pharmacokinetic Studies of Gefitinib

Swaisland, H., Smith, R. P., Laight, A., Kerr, D. J., Ranson, M., Wilder‐Smith, C. H., & Duvauchelle, T. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00004 · Cited by 142

Cytochrome P450-dependent metabolism of gefitinib

McKillop, D., McCormick, A., Millar, A., Miles, G. S., Phillips, P. J., & Hutchison, M. (2005) · Xenobiotica · doi:10.1080/00498250400026464 · Cited by 138

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

Stopfer, P., Marzin, K., Narjes, H., Gansser, D., Shahidi, M., Uttereuther-Fischer, M., & Ebner, T. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1803-9 · Cited by 137

Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population

Ma, S., Xu, Y., Deng, Q., & Yu, X. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.028 · Cited by 127

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

Yi, H. G., Kim, H. J., Kim, Y. J., Han, S., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Kim, C. S., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.016 · Cited by 125

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

McKillop, D., Partridge, E. A., Kemp, J. V., Spence, M. P., Kendrew, J., Barnett, S., Wood, P. G., Giles, P. B., Patterson, A. B., Bichat, F., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0329 · Cited by 125

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Solassol, I., Pinguet, F., & Quantin, X. (2019) · Biomolecules · doi:10.3390/biom9110668 · Cited by 129

Metabolism considerations for kinase inhibitors in cancer treatment

Duckett, D. R., & Cameron, M. D. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.506873 · Cited by 113

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Scheffler, M., Gion, P. D., Doroshyenko, O., Wolf, J., & Fuhr, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587020-000000000-00000 · Cited by 110

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer

Lee, Y. J., Choi, H. J., Kim, S. I., Chang, J., Moon, J. W., Park, I. K., Kim, J.-H., & Cho, B. C. (2010) · Cancer · doi:10.1002/cncr.24877 · Cited by 106

CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

Li, J., Karlsson, M. O., Brahmer, J. R., Spitz, A. N., Zhao, M., Hidalgo, M. M., & Baker, S. D. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj466 · Cited by 106

Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities

Li, X., Kamenecka, T. M., & Cameron, M. D. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900256y · Cited by 105

Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase

Wang, J.-Q., Gao, M., Miller, K. D., Sledge, G. W., & Zheng, Q. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.080 · Cited by 97

Biotransformation and bioactivation reactions of alicyclic amines in drug molecules

Bolleddula, J., DeMent, K., Driscoll, J. P., Worboys, P. D., Brassil, P. J., & Bourdet, D. L. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.924962 · Cited by 87

Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites

Lacy, S. A., Hsu, B. H., Miles, D., Aftab, D. T., Wang, R., & Nguyen, L. T. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063610 · Cited by 82

Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors

Bergman, E., Forsell, P., Persson, E. M., Knutson, L., Dickinson, P. A., Smith, R. P., Swaisland, H., Farmer, M. R., Cantarini, M., & Lennernäs, H. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.002 · Cited by 69

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Dennis, M., Davies, M., Oliver, S. D., D'Souza, R. A., Pike, L., & Stockman, P. K. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1939-2 · Cited by 68

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non–Small-Cell Lung Cancer

Kobayashi, H., Sato, K., Niioka, T., Miura, H., Ito, H., & Miura, M. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.004 · Cited by 61

In vitrometabolism of gefitinib in human liver microsomes

McKillop, D., McCormick, A., Miles, G. S., Phillips, P. J., Pickup, K., Bushby, N., & Hutchison, M. (2004) · Xenobiotica · doi:10.1080/02772240400015222 · Cited by 61

Recent advances in metabolism and toxicity of tyrosine kinase inhibitors

Zhao, Q., Wu, Z. E., Li, B., & Li, F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108256 · Cited by 57

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

Rukazenkov, Y., Speake, G., Marshall, G. B., Anderton, J., Davies, B. R., Wilkinson, R. W., Hickinson, D. M., & Swaisland, A. J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833034e1 · Cited by 59

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Xu, Z., & Li, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194870 · Cited by 60

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib

Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., Nakamura, T., & Yamamoto, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7340 · Cited by 59

A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans

Bi, Y., Deng, J., Murry, D. J., & An, G. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9836-3 · Cited by 54

Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism

Liu, X., Lu, Y., Guan, X., Dong, B., Chavan, H. D., Wang, J., Zhang, Y., Krishnamurthy, P. C., & Li, F. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.010 · Cited by 51

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

Chen, Y., Wang, M., Zhong, W., & Zhao, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.013 · Cited by 48

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog

McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S., Parry, A. C., Bardsley, J., Woodman, H. M., & Swaisland, H. (2004) · Xenobiotica · doi:10.1080/00498250400009189 · Cited by 46

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

Alfieri, R. R., Galetti, M., Tramonti, S., Andreoli, R., Mozzoni, P., Cavazzoni, A., Bonelli, M. A., Fumarola, C., Monica, S. L., Galvani, E., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-143 · Cited by 46

Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes

Han, S., Zhao, H., Zhou, N., Zhou, F., & Li, P. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.10.021 · Cited by 44

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

Pratz, K. W., & Levis, M. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801895352 · Cited by 44

A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism

Barzi, M., Pankowicz, F. P., Zorman, B., Liu, X., Legras, X. D., Yang, D., Borowiak, M., Bissig-Choisat, B., Sumazin, P., Li, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00049-x · Cited by 43

Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

Paludetto, M., Puisset, F., Chatelut, É., & Arellano, C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21577 · Cited by 43

Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents

Min, J., Guo, K., Suryadevara, P. K., Zhu, F., Holbrook, G., Chen, Y., Féau, C., Young, B. M., Lemoff, A. S., Connelly, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01092 · Cited by 42

Does Sarcopenia Affect Outcome in Patients with Non-Small-Cell Lung Cancer Harboring EGFR Mutations?

Rossi, S., Noia, V. D., Tonetti, L., Strippoli, A., Basso, M., Schinzari, G., Cassano, A., Leone, A., Barone, C., & D’Argento, E. (2018) · Future Oncology · doi:10.2217/fon-2017-0499 · Cited by 40

Physicochemical Properties of Epidermal Growth Factor Receptor Inhibitors and Development of a Nanoliposomal Formulation of Gefitinib

Trummer, B. J., Iyer, V., Balu‐Iyer, S. V., O'Connor, R. A., & Straubinger, R. M. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23180 · Cited by 39

Gefitinib–phenytoin interaction is not correlated with the14C‐erythromycin breath test in healthy male volunteers

Chhun, S., Verstuyft, C., Rizzo‐Padoin, N., Simoneau, G., Becquemont, L., Idy-Peretti, I., Swaisland, A. J., Wortelboer, R., Bergmann, J., & Mouly, S. J. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03438.x · Cited by 39

Successful Treatment of Carcinomatous Meningitis with Gefitinib in a Patient with Lung Adenocarcinoma Harboring a Mutated EGF Receptor Gene

Fukuhara, T., Saijo, Y., Sakakibara, T., Inoue, A., Morikawa, N., Kanamori, M., Nakashima, I., & Nukiwa, T. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.214.359 · Cited by 37

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

Horák, J., White, J., Harris, A. L., Verrill, M. W., Carmichael, J., Holt, A., Cantarini, M., Macpherson, M. P., Swaisland, A. J., Swaisland, H., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1611-2 · Cited by 35

The use of the dog electroencephalogram (EEG) in safety pharmacology to evaluate proconvulsant risk

Dürmüller, N., Guillaume, P., Lacroix, P., Porsolt, R. D., & Moser, P. C. (2007) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2007.03.006 · Cited by 35

Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis

Selvarajah, G. T., Verheije, M. H., Kik, M. J. L., Slob, A., Rottier, P. J. M., Mol, J. A., & Kirpensteijn, J. (2012) · The Veterinary Journal · doi:10.1016/j.tvjl.2012.02.009 · Cited by 35

Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines

Galetti, M., Alfieri, R. R., Cavazzoni, A., Monica, S. L., Bonelli, M. A., Fumarola, C., Mozzoni, P., Palma, G. D., Andreoli, R., Mutti, A., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.033 · Cited by 34

Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib

Kobayashi, H., Sato, K., Niioka, T., Takeda, M., Okuda, Y., Asano, M., Ito, H., & Miura, M. (2016) · Medical Oncology · doi:10.1007/s12032-016-0773-5 · Cited by 32

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro

Festuccia, C., Gravina, G. L., Biordi, L. A., D’Ascenzo, S., Dolo, V., Ficorella, C., Ricevuto, E., & Tombolini, V. (2009) · The Prostate · doi:10.1002/pros.20995 · Cited by 31

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases

Luo, S., Chen, L., Chen, X., & Xie, X. (2015) · Oncotarget · doi:10.18632/oncotarget.4264 · Cited by 30

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

Nijenhuis, C. M., Schellens, J. H. M., & Beijnen, J. H. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1181081 · Cited by 30

Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting

Cass, Y., Connor, T. H., & Tabachnik, A. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216637217 · Cited by 30

Decreased Biosynthesis of Lung Surfactant Constituent Phosphatidylcholine Due to Inhibition of Choline Transporter by Gefitinib in Lung Alveolar Cells

Ishiguro, N., Oyabu, M., Sato, T., Maeda, T., Minami, H., & Tamai, I. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9362-9 · Cited by 28

Metabolite characterization of a novel anti‐cancer agent, icotinib, in humans through liquid chromatography/quadrupole time‐of‐flight tandem mass spectrometry

Liu, D., Jiang, J., Zhang, L., Tan, F., Wang, Y., & Hu, P. (2011) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.5061 · Cited by 26

Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition

McKillop, D., Guy, S. P., Spence, M. P., Kendrew, J., Kemp, J. V., Bushby, N., Wood, P. G., Barnett, S., & Hutchison, M. (2006) · Xenobiotica · doi:10.1080/00498250500523253 · Cited by 25

Gefitinib for the treatment of non-small-cell lung cancer

Campbell, L., Blackhall, F. H., & Thatcher, N. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.481283 · Cited by 25

In vitrometabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

Nakagawa, T., Fowler, S. M., Takanashi, K., Youdim, K. A., Yamauchi, T., Kawashima, K., Sato-Nakai, M., Yu, L. J., & Ishigai, M. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1344910 · Cited by 22

Metabolites of alectinib in human: their identification and pharmacological activity

Sato-Nakai, M., Kawashima, K., Nakagawa, T., Tachibana, Y., Yoshida, M., Takanashi, K., Morcos, P. N., Binder, M., Moore, D. J., & Yu, L. J. (2017) · Heliyon · doi:10.1016/j.heliyon.2017.e00354 · Cited by 22

Gefitinib in the treatment of advanced non-small-cell lung cancer

Reck, M. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.1 · Cited by 22

Intratumoral Modeling of Gefitinib Pharmacokinetics and Pharmacodynamics in an Orthotopic Mouse Model of Glioblastoma

Sharma, J., Lv, H., & Gallo, J. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0690 · Cited by 21

Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

Couñago, F., Pérez, A. R., Calvo, P., Luna, J., Monroy, J. L., Taboada, B., Díaz, V. D., & de Dios, N. R. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1512-2 · Cited by 21

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment

Kim, H.-R., Lee, J. C., Kim, Y., Kim, K. S., Oh, I., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.008 · Cited by 21

Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer

Wang, F., Ning, F., Liu, C., Hao, Y., Li, L., Yu, Z., Chen, S., & Li, B. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0286-9 · Cited by 20

Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3

Sato, T., Ito, H., Hirata, A., Abe, T., Mano, N., & Yamaguchi, H. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1275880 · Cited by 19

Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer

Kawata, T., Higashimori, M., Itoh, Y., Tomkinson, H. K., Johnson, M. G., Tang, W., Nyberg, F., Jiang, H., & Tanigawara, Y. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03788-4 · Cited by 18

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer

Yuan, Y., Li, X., Chen, J., Dong, Weng, S., & Huang, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s34124 · Cited by 17

Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu

Piechocki, M. P., Dibbley, S. K., Lonardo, F., & Yoo, G. H. (2007) · International Journal of Cancer · doi:10.1002/ijc.23231 · Cited by 17

Tyrosine Kinase Inhibitors

Cismowski, M. J. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.61004-9 · Cited by 16

Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans

Scholler, J., & Levêque, D. (2011) · Oncology Reviews · doi:10.1007/s12156-011-0072-5 · Cited by 16

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

Luong, T.-L. T., McAnulty, M. J., Evers, D. L., Reinhardt, B. J., & Weina, P. J. (2021) · Current Research in Toxicology · doi:10.1016/j.crtox.2021.05.006 · Cited by 15

Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry

Wang, C., Zhang, J., Zhou, S., Yu, L., Han, F., Ling, R., & Ling, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236523 · Cited by 15

Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients

Guan, Y., Li, M., He, Q. W., Li, M., & Luo, F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s80635 · Cited by 15

Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan

Lin, C., Hsu, K.-H., Chang, S., Tsou, H., Sheehan, J. P., Sheu, M., & Pan, H.-C. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0431-7 · Cited by 15

Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers

Gerisch, M., Schwarz, T., Lang, D. H., Rohde, G., Reif, S., Genvresse, I., Reschke, S., van der Mey, D., & Granvil, C. P. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3383-9 · Cited by 15

Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4

Nair, P. C., McKinnon, R. A., & Miners, J. O. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085167 · Cited by 16

The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor

Högnäsbacka, A., Poot, A. J., Vugts, D. J., van Dongen, G. A. M. S., & Windhorst, A. D. (2022) · Pharmaceuticals · doi:10.3390/ph15040450 · Cited by 14

The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro

Samén, E., Thorell, J.-O., Fredriksson, A., & Stone‐Elander, S. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.09.008 · Cited by 14

Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer

Guan, S., Chen, X., Xin, S., Liu, S., Yang, Y., Fang, W., Huang, Y., Zhao, H., Zhu, X., Zhuang, W., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100951 · Cited by 13

Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS

Molloy, B. J., King, A. M., Mullin, L. G., Gethings, L. A., Riley, R. J., Plumb, R. S., & Wilson, I. D. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1859643 · Cited by 13

High Throughput UHPLC-MS-Based Lipidomics Using Vacuum Jacketed Columns

Plumb, R. S., Isaac, G., Rainville, P. D., Hill, J. F., Gethings, L. A., Johnson, K. A., Lauterbach, J. D., & Wilson, I. D. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00836 · Cited by 13

Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors

Lyu, J., Yang, N., Xiao, L., Nie, X., Xiong, J., Liu, Y., Zhang, M., Zhang, H., Tang, C., Pan, S., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1113875 · Cited by 12

HB-EGF activates EGFR to induce reactive neural stem cells in the mouse hippocampus after seizures

Pastor-Alonso, O., Durá, I., Bernardo-Castro, S., Varea, E., Muro‐García, T., Martín‐Suárez, S., Encinas, J. M., & Pineda, J. R. (2024) · Life Science Alliance · doi:10.26508/lsa.202201840 · Cited by 12

Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity

Zhao, C., Hao, H., Zhao, H., Ren, W., Jiao, Y., An, G., Sun, H., Han, S., & Li, P. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112770 · Cited by 12

The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC–IM–MS Study

Molloy, B. J., Mullin, L. G., King, A. M., Gethings, L. A., Plumb, R. S., & Wilson, I. D. (2021) · Metabolites · doi:10.3390/metabo11060379 · Cited by 11

Method validation and characterization of stress degradation products of gefitinib through UPLC-UV/PDA and LC–MS/TOF studies

Patra, S. R., Bali, A., Saha, M., Singh, J., & Shekhar, S. (2023) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2023.117070 · Cited by 11

Hybrid organic/inorganic hybrid surface technology for increasing the performance of LC/MS(MS)-based drug metabolite identification studies: Application to gefitinib and metabolites in mouse plasma and urine

Plumb, R. S., Gethings, L. A., King, A. M., Mullin, L. G., Maker, G. L., Trengove, R. D., & Wilson, I. D. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114076 · Cited by 11

Improving LC/MS/MS-based bioanalytical method performance and sensitivity via a hybrid surface barrier to mitigate analyte – Metal surface interactions

Tanna, N., Mullin, L. G., Rainville, P. D., Wilson, I. D., & Plumb, R. S. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122825 · Cited by 11

Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine

Luong, T.-L. T., Powers, C. N., Reinhardt, B. J., & Weina, P. J. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100112 · Cited by 10

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy

Guan, S., Chen, X., Chen, Y., Wan, G., Su, Q., Liang, H., Yang, Y., Fang, W., Huang, Y., Zhao, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.006 · Cited by 10

Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation

Igawa, S., Kasajima, M., Ishihara, M., Kimura, M., Hiyoshi, Y., Niwa, H., Kusuhara, S., Harada, S., Asakuma, M., Otani, S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2570-1 · Cited by 10

Derivative Spectrophotometric Methods for Determination of Gefitinib in Bulk and in Formulation

Patra, S. R., Bali, A., & Saha, M. (2021) · Journal of Applied Spectroscopy · doi:10.1007/s10812-021-01284-3 · Cited by 8

Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells

Zhu, G., Zhao, Y., Zhang, W., Wu, Y., Liu, Y., Guo, G., Wang, X., & Liu, Z. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108466 · Cited by 8

Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces

Gao, X., Zhang, Y., Feng, T., Cao, L., Wu, W., & Qin, K. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1859642 · Cited by 8

Detection of pharmacolipidodynamic effects following the intravenous and oral administration of gefitinib to C57Bl/6JRj mice by rapid UHPLC-MS analysis of plasma

Plumb, R. S., Gethings, L. A., Isaac, G., Munjoma, N. C., & Wilson, I. D. (2024) · Scientific Reports · doi:10.1038/s41598-024-66764-w · Cited by 7

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog

McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S., Parry, A. C., Bardsley, J., Woodman, H. M., & Swaisland, H. (2004) · Xenobiotica · doi:10.1080/00498250400009189 · Cited by 46

In vitrometabolism of gefitinib in human liver microsomes

McKillop, D., McCormick, A., Miles, G. S., Phillips, P. J., Pickup, K., Bushby, N., & Hutchison, M. (2004) · Xenobiotica · doi:10.1080/02772240400015222 · Cited by 61

Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor

Scheers, E. M., Borgmans, C., Keung, C., Bohets, H., Wynant, I., Poggesi, I., Cuyckens, F., Leclercq, L., & Mamidi, R. N. V. S. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1821123 · Cited by 12

Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces

Gao, X., Zhang, Y., Feng, T., Cao, L., Wu, W., & Qin, K. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1859642 · Cited by 8

Cytochrome P450-dependent metabolism of gefitinib

McKillop, D., McCormick, A., Millar, A., Miles, G. S., Phillips, P. J., & Hutchison, M. (2005) · Xenobiotica · doi:10.1080/00498250400026464 · Cited by 138